Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Oral ivermectin safe,...

    Oral ivermectin safe, effective in scabies in children weighing less than 15 Kg

    Written by Medha Baranwal Baranwal Published On 2019-10-28T19:20:41+05:30  |  Updated On 28 Oct 2019 7:20 PM IST
    Oral ivermectin safe, effective in scabies in children weighing less than 15 Kg

    France: Oral ivermectin is safe and effective for the treatment of scabies in infants and children weighing < 15 kg, finds a recent study published in the British Journal of Dermatology.


    According to WHO, scabies is a parasitic infestation caused by Sarcoptes scabiei var hominis. The microscopic mite burrows into the skin and lays eggs, eventually triggering a host immune response that leads to intense itching and rash.


    Scabies occurs frequently in infants and children. Till now, only tropical treatments have been approved in infants and some of them are poorly tolerated. Oral ivermectin, although approved for the treatment of scabies in several countries, its use in infants and children weighing < 15 kg is off label.


    Franck Boralevi, Bordeaux University Hospital, Bordeaux, France, and colleagues conducted the study to assess the safety of ivermectin in infants and young children and to collect data on ivermectin efficacy in these age groups.


    The study involved 170 infants and children aged 1-64 months from dermatology and paediatric dermatology departments of 28 French centres between July 2012 and November 2015. The participants had a bodyweight of 4-14·5 kg and were treated with oral ivermectin. Physicians treating the children were asked to send back a completed standardized and anonymous questionnaire, and the data were analysed.


    The mean dose received was 223 μg kg-1 and 89% of the patients received a systematic second dose. Concomitant topical treatment was administered to 73% of patients.


    Key findings include:

    • Adverse events were reported in seven patients (4%) and were not severe.

    • At the follow-up visit, 139 (85%) patients had achieved healing.

    • Factors significantly associated with healing were an ivermectin dose > 200 μg kg-1, and a delay between those two doses of < 10 days.


    "Our findings suggest the safety and efficacy of ivermectin for the treatment of scabies in infants and young children," concluded the authors.


    More Information: "Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study" published in the British Journal of Dermatology.


    DOI: https://doi.org/10.1111/bjd.18369


    Journal Information: British Journal of Dermatology

    British Journal of DermatologychildrenFranck BoraleviinfantsIvermectinMedical newsoral treatmentrabiesrecent medical news
    Source : British Journal of Dermatology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok